Mode
Text Size
Log in / Sign up

Trachoma

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for trachoma

6 trials tracked for trachoma: 3 in phase 3 or 4 and 2 with published results. The most-cited published study has 34 citations.

6Trials tracked
3Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 3 Phase 1 1 Other / NA 2
  1. Phase 4 Partnership for Rapid Elimination of Trachoma Completed · 34 cited
  2. Phase 4 Azithromycin Reduction to Reach Elimination of Trachoma Completed · 5 cited
  3. Phase 4 Impact of Two Alternative Dosing Strategies for Trachoma Control in Niger Completed
  4. Phase 1 Safety and Immunogenicity of a Chlamydia Vaccine CTH522 Completed
  5. N/A Modified Instrumentation for Surgery to Correct Trichiasis Completed
  6. N/A A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Trachoma: what the trials found

Azithromycin is established as a primary intervention for trachoma in large-scale clinical evaluations [1, 3].

Long-term monitoring of community prevalence of Trachoma and Ocular C. Trachomatis (CT) infection following azithromycin treatment showed no statistically significant difference across various groups at 36 months (p=0.22) 2.

Recent results — preliminary, needs further review

  • Surveillance and treatment with azithromycin for newcomer and traveler families did not show a statistically significant difference in the proportion of communities with C. Trachomatis infection prevalence of 1% or below (p=>0.05) 5.
  • The use of azithromycin for newcomer and traveler families did not result in a statistically significant difference in the proportion of communities with clinical trachoma prevalence of 5% or below (p=1) 5.
  • CTH522-CAF01 IM is currently undergoing early-phase investigation but results are not yet corroborated 4.
  • The TT Clamp is under investigation but findings are not yet corroborated 6.

For the clinician treating this condition

  • Azithromycin is a standard intervention for trachoma, supported by large-scale phase 4 trials [1, 3].
  • Long-term community prevalence of Trachoma and Ocular C. Trachomatis (CT) infection did not show significant changes at the 36-month mark following azithromycin administration 2.

AI synthesis of 4 cited trials, updated Jun 26, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.